Lepur - Lepur is a hypolipidemic agent from a group of statins, an inhibitor of HMG-CoA reductase. This medication is a prodrug because it has in its structure the closed lactone ring which is hydrolyzed after intake.
Lipid-lowering effect of statins is associated with lower levels of total cholesterol by LDL-C. Reducing cholesterol is dose-dependent and is not linear but exponential. Statins do not affect the activity of lipoprotein and hepatic lipase, have no significant effect on the synthesis and catabolism of free fatty acids, thats why their effect on TG levels again and indirectly through their main effects on reducing LDL-C.
According to the controlled studies of Lepur increases HDL-C to 14%.
In addition to the hypolipidemic actions Lepur has beneficial effects in endothelial dysfunction (pre-clinical sign of early atherosclerosis), on the vascular wall, the state of atheroma, improves blood rheology, have antioxidant, antiproliferative properties. There is evidence that Lepur improves endothelial function within 30 days of therapy.
Lepur therapy was accompanied by a decrease in the incidence of cardiovascular disorders, regardless of baseline LDL-C.
Adjunct to diet for treatment of hypercholesterolaemia. Patients at high risk of CHD (w/ or w/o hypercholesterolaemia) including diabetics, those w/ history of stroke or other CV disease, peripheral vessel disease, or w/ existing CHD to reduce the risk of CV death, major CV events including stroke, & hospitalisation due to angina pectoris.